Fortrea supports structural heart programs that use transcatheter and surgical approaches to treat valve disease and other structural conditions. Our experience covers aortic, mitral and tricuspid valve repair and replacement, surgical heart valves, annuloplasty systems and left atrial appendage closure devices. We support the full lifecycle, from early feasibility and first-in-human studies through pivotal, post-approval and registry studies. That includes selecting experienced implanting centres and coordinating imaging and long-term follow-up.

Our teams support interventions that restore blood flow and treat vascular disorders. Indications include coronary artery disease, acute coronary syndrome, peripheral artery disease, and abdominal and thoracic aortic aneurysms.  Device types include coronary and peripheral drug-eluting stents, drug-coated balloons, endovascular and thoracic aortic stent grafts, venous stents and thrombectomy systems. We also support studies that need long-term follow-up across multiple countries.

Fortrea supports the clinical development of pacing, defibrillation, electrophysiology and rhythm-monitoring technologies. Our experience includes permanent and leadless pacemakers, implantable cardioverter-defibrillators (ICDs), cardiac resynchronisation therapy (CRT) devices, ablation catheters and implantable loop recorders. Atrial fibrillation is one of the top indications in our cardiovascular device portfolio.

We support evidence generation for cardiovascular diagnostic devices, IVDs and biomarker-based technologies, as well as imaging solutions. Our support spans clinical performance studies and regulatory pathways under FDA, EU MDR/IVDR and UK requirements. Integrated data management, biostatistics and quality oversight help produce robust evidence for regulatory, reimbursement and commercial decisions.

Fortrea has experience with connected technologies, wearable devices, software-enabled medical technologies and remote patient monitoring, including heart failure monitoring technologies. We help sponsors design studies that capture continuous, real-world data and handle the data integrity and usability needs specific to digital health.

Yes. Fortrea conducts cardiovascular studies across established and emerging markets, supporting site selection, study execution and patient recruitment worldwide.

Yes. Fortrea supports cardiovascular development from early feasibility and first-in-human studies through pivotal trials, post-approval studies, registries and post-market research.

Fortrea offers clinical operations, project management, medical monitoring, regulatory support, data management, biostatistics, safety, patient recruitment and quality oversight throughout the study lifecycle.

Yes. Fortrea supports post-market clinical follow-up (PMCF), post-market performance follow-up (PMPF), registries, long-term follow-up studies, performance evaluation studies, and real-world evidence (RWE) programmes.

A CRO can provide global study delivery, regulatory support and operational capabilities across feasibility, pivotal and post-market studies.